Amyris is a company within the Biotechnology category. Amyris is a synthetic biology company that designs, develops, and manufactures sustainable ingredients for various industries, including beauty, health, and wellness. The 'historicrestructuring' refers to the company's recent significant corporate and financial reorganization, including Chapter 11 bankruptcy proceedings and asset divestitures.
Amyris was founded in 2003 and is headquartered in Emeryville, California.
Amyris is rated Low Visibility on the Optimly Brand Authority Index, a measure of how well AI models can accurately describe the brand. The exact score is locked for unclaimed profiles.
AI narrative accuracy for Amyris is Weak. Significant factual deltas detected. Inconsistent representation across models.
AI models classify Amyris as a Misread. Visible but inaccurate.
Amyris appeared in 4 of 5 sampled buyer-intent queries (80%). While general queries about Amyris's products, historical business, and the bankruptcy itself are discoverable, specific details regarding its post-restructuring executive team, full impact on all product lines, and the long-term strategic direction may be less prominent or fragmented across search results.
AI descriptions, if based on historical data, would likely focus on Amyris's innovations in synthetic biology and its portfolio of sustainable ingredients and consumer brands. However, the 'historicrestructuring' indicates a significant shift, suggesting that any existing AI perception is potentially inaccurate regarding its current stability, ownership, or strategic direction. Key gap: Information regarding Amyris's current operational status and financial health is likely outdated or conflicting due to recent restructuring events, including bankruptcy filings and asset sales, which fundamentally alter the company's profile.
Of 3 key facts verified about Amyris, 1 are well-documented (likely accurate across AI models), 1 have limited sourcing, and 1 are retrieval-dependent and may be inaccurate without live search.
The primary vulnerability is the potential for AI models to provide outdated or misleading information regarding Amyris's financial stability, operational status, and future viability, given its recent restructuring and bankruptcy proceedings. This could severely misinform stakeholders.
Buyers turn to Amyris for Financial distress, Company restructuring, Supply chain disruption, among 5 documented problem areas.
Buyers evaluating Amyris typically ask AI models about "Find alternative ingredient suppliers", "Understand bankruptcy process", "Assess investment recovery options", and 2 similar queries.
Buyers commonly compare Amyris with Evaluate company viability post-restructuring, Assess financial health and liabilities, Analyze market impact of restructuring, among 5 documented comparison brands.
Amyris's core products are Sustainable ingredients (e.g., squalane, hemisqualane, cannabinoids) and consumer brands (e.g., Biossance, JVN, Rose Inc.)..
Amyris uses B2B ingredient sales; D2C and retail for consumer brands..
Amyris serves Beauty, health and wellness, flavors and fragrances, renewable fuels..
Amyris Proprietary synthetic biology platform for developing and scaling bio-fermented ingredients sustainably.
Brand Authority Index (BAI) tier: Low Visibility (exact score locked for unclaimed brands)
Archetype: Misread
https://optimly.ai/brand/amyris-historicrestructuring
Last analyzed: June 30, 2026
Founded: 2003
Headquarters: Emeryville, California
This profile is part of the Optimly Brand Trust Registry — a verified index of 60,000+ brand profiles that AI models read from when answering buyer-intent questions about brands and categories. Optimly identifies which third-party sources AI cites about each brand, prepares structured brand information for those sources, and measures whether AI representation improves.
If this is your brand, you can claim this profile to verify its contents and correct what AI models say about you: Claim this profile